Signal99e496b1

WEBINDEXED

SEC probes Pfizer for irregular accounting of COVID vaccine returns inflating 2023 revenue by $1B.

Author:sec.gov

Published:2024-10-11 15:00 UTC

Occurred:2024-10-09 00:00 UTC

Received:2026-04-15 08:00 UTC

Status Score

92%

ITG

94%

IMP

90%

NAR

84%

Analysis Insights

Topics Detected

#Accounting Irregularities#SEC Investigation

Entities Mentioned

@SEC@Pfizer

Technical Details

Analyst Mission

Financial Integrity8e677976...

Source IDN/A

Original URLN/A

Database ID99e496b1-945e-49cc-8b5d-d9d78e8faa90

Raw Data

{
  "id": "99e496b1-945e-49cc-8b5d-d9d78e8faa90",
  "content": "SEC probes Pfizer for irregular accounting of COVID vaccine returns inflating 2023 revenue by $1B.",
  "url": null,
  "source_type": "web",
  "source_id": null,
  "author_id": "sec.gov",
  "published_at": "2024-10-11T15:00:00.000Z",
  "received_at": "2026-04-15T08:00:25.282Z",
  "status": "indexed",
  "relevance_score": 92,
  "case_id": null,
  "metadata": {
    "topics": [
      "Accounting Irregularities",
      "SEC Investigation"
    ],
    "mission": "Financial Integrity",
    "mentions": [
      "SEC",
      "Pfizer"
    ],
    "mission_id": "8e677976-d5f5-4d22-bc95-c0ed9fe0ae73"
  },
  "credibility_score": 94,
  "actionability_score": 90,
  "emotional_score": 84,
  "occurred_at": "2024-10-09T00:00:00.000Z",
  "case_ids": null
}